Compare 3M Company (MMM) vs Merck & Co., Inc. (MRK) Price & Performance

3M CompanyTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

3M Company vs Merck & Co., Inc. — how do they compare? 3M Company trades at $170.8 (market cap $82.99B), while Merck & Co., Inc. trades at $126.14 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 3.7× 3M Company's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.

	MMM	MRK
Market Cap	$82.99B	$307.25B
Sector	Industrials	Health
52-Week High	$174.61	$129.52
52-Week Low	$141.10	$77.60
Enterprise Value	$91.39B	$350.66B
Dividend Yield	1.96%	2.73%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

3M Company

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MMM

3M beats Q2 earnings and raises outlook, driven by growth in optics and industrial segments.Seeking Alpha · 5 hours agoBullish 3M shares jump 10% after beating Q2 earnings and raising full-year EPS forecastGordon Thompson · 7 hours agoBullish 3M shares jump 9% after Q2 earnings beat and raised 2026 guidanceProactive Investors · 12 hours agoBullish View details →

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.